# Lower Muscle and Blood Lactate Accumulation in Sickle Cell Trait Carriers in Response to Short High-Intensity Exercise

Laurent Messonnier, Samuel Oyono-Enguéllé, Lucile Vincent, Hervé

Dubouchaud, Benjamin Chatel, Hervé Sanchez, Alexandra Malgoyre, Cyril

Martin, Frédéric Galactéros, Pablo Bartolucci, et al.

► To cite this version:

Laurent Messonnier, Samuel Oyono-Enguéllé, Lucile Vincent, Hervé Dubouchaud, Benjamin Chatel, et al.. Lower Muscle and Blood Lactate Accumulation in Sickle Cell Trait Carriers in Response to Short High-Intensity Exercise. Nutrients, 2022, 14 (3), pp.501. 10.3390/nu14030501. hal-04555819

HAL Id: hal-04555819

https://hal.univ-grenoble-alpes.fr/hal-04555819v1

Submitted on 26 Feb 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
Article

# Lower Muscle and Blood Lactate Accumulation in Sickle Cell Trait Carriers in Response to Short High-Intensity Exercise

Laurent A. Messonnier <fnref n="1" />*, Samuel Oyono-Enguéllé <fnref n="2" />,†, Lucile Vincent <fnref n="1" />, Hervé Dubouchaud <fnref n="3" />,†,
Benjamin Chatel <fnref n="1" />,†, Hervé Sanchez <fnref n="4" />, Alexandra Malgoyre <fnref n="4" />, Cyril Martin <fnref n="5" />, Frédéric Galactéros <fnref n="6" />,
Pablo Bartolucci <fnref n="6" />,†, Patrice Thiriet <fnref n="5" /> and Léonard Féasson <fnref n="7" />,<fnref n="8" />,†

<figure><img src="image_2.png" /></figure>

check for
updates

**Citation:** Messonnier, L.A.; Oyono-Enguéllé, S.; Vincent, L.; Dubouchaud, H.; Chatel, B.; Sanchez, H.; Malgoyre, A.; Martin, C.; Galactéros, F.; Bartolucci, P.; et al. Lower Muscle and Blood Lactate Accumulation in Sickle Cell Trait Carriers in Response to Short High-Intensity Exercise. *Nutrients* **2022**, *14*, 501. https://doi.org/10.3390/nu14030501

Academic Editor: Giorgos K. Sakkas

Received: 31 October 2021
Accepted: 18 January 2022
Published: 24 January 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_3.png" /></figure>

**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

**Abstract:** It remains unclear whether sickle cell trait (SCT) should be considered a risk factor during intense physical activity. By triggering the polymerization-sickling-vaso-occlusion cascade, lactate accumulation-associated acidosis in response to high-intensity exercise is believed to be one of the causes of complications. However, our understanding of lactate metabolism in response to high-intensity exercise in SCT carriers is incomplete. Thirty male SCT carriers (n = 15) and healthy subjects (n = 15) with and without α-thalassemia performed a 2-min high-intensity exercise. Blood and muscle lactate concentrations were measured at exercise completion. Time courses of blood lactate and glucose concentrations were followed during the subsequent recovery. Additional biochemical analyses were performed on biopsies of the *vastus lateralis* muscle. SCT was associated with lower blood and muscle lactate concentrations in response to the short high-intensity exercise. Compared to controls, the muscle content among SCT carriers of lactate transporter MCT4 and β₂-adrenergic receptor were higher and lower, respectively. During recovery, the lactate removal ability was higher in SCT carriers. In the present study, no effect of α-thalassemia was observed. The lower blood and muscle lactate accumulations in SCT carriers may, to some extent, act as protective mechanisms: (i) against exercise-related acidosis and subsequent sickling, that may explain the relatively rare complications observed in exercising SCT carriers; and (ii) against the deleterious effects of intracellular lactate and associated acidosis on muscle function, that might explain the elevated presence of SCT carriers among the best sprinters.

**Keywords:** lactate transport; pH regulation; gluconeogenesis; recovery

<footnote n="1">¹ Université Savoie Mont Blanc, Laboratoire Interuniversitaire de Biologie de la Motricité, EA 7424, F-73000 Chambéry, France; lucile74.xxc@gmail.com (L.V.); benjamin.chatel@live.fr (B.C.)</footnote>

<footnote n="2">² Université de Yaoundé 1, Laboratoire de Physiologie, Faculté de Médecine et des Sciences Biomédicales, Yaoundé, Cameroon; hubert.freund@wanadoo.fr</footnote>

<footnote n="3">³ Université Grenoble Alpes, Inserm, LBFA, F-38000 Grenoble, France; herve.dubouchaud@univ-grenoble-alpes.fr</footnote>

<footnote n="4">⁴ Institut de Recherche Biomédicale des Armées, Unité Physiologie de l'Exercice et des Activités en Conditions Extrêmes, F-91223 Brétigny-sur-Orge, France; hsanchez@mtraining.fr (H.S.); alexandra.malgoyre@intradef.gouv.fr (A.M.)</footnote>

<footnote n="5">5 Université de Lyon, Université Claude Bernard Lyon 1, Laboratoire Interuniversitaire de Biologie de la Motricité, EA 7424, F-69100 Villeurbanne, France; cyril.martin@univ-lyon1.fr (C.M.); patrice.thiriet@univ-lyon1.fr (P.T.)</footnote>

<footnote n="6">6 Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital-UPEC, AP-HP, F-94000 Créteil, France; frederic.galacteros@aphp.fr (F.G.); pablo.bartolucci@aphp.fr (P.B.)</footnote>

<footnote n="7">7 Université de Lyon, Université Jean Monnet Saint-Etienne, Laboratoire Interuniversitaire de Biologie de la Motricité, EA 7424, F-42000 Saint-Etienne, France; leonard.feasson@univ-st-etienne.fr</footnote>

<footnote n="8">8 Referent Center of Neuromuscular Diseases Euro-NmD, Myology Unit, Department of Clinical and Exercise Physiology, University Hospital of Saint-Etienne, F-42055 Saint-Etienne, France</footnote>

<footnote>* Correspondence: laurent.messonnier@univ-smb.fr; Tel.: +33-4-79-75-81-85; Fax: +33-4-79-75-81-45</footnote>

<footnote>† Deceased.</footnote>
# 1. Introduction

Disagreement exists about whether sickle cell trait (SCT) carriage should be consid-
ered a benign condition or a risk factor during intense physical activity [1–6]. Considering
SCT a risk factor is based on the fact that during high-intensity exercise, SCT carriers are
prone to hemorrhological disturbances (augmented blood viscosity, decreased red blood
cell deformability and increased endothelial activation), intravascular coagulation and
sickling [7–11]. SCT as a risk factor becomes particularly important when intense exercise is
performed at altitude, and is associated with dehydration or hyperthermia. In such circum-
stances, serious complications (such as heat stroke, hyperkalemia, hematuria, pulmonary
edema, cardiac arrhythmias and ischemia, splenic infarction, renal failure, myalgias, vaso-
occlusion crisis (VOC) and fulminant rhabdomyolysis) have been reported, which can
ultimately lead to sudden death [3,5,12–16]. Moreover, the occurrence of complications,
collapse and sudden death during the first 30–60 min following high-intensity exercise¹⁴
demonstrates the need to pay particular attention to this apparently critical postexercise
period in SCT carriers.

High-intensity exercise induces significant activation of glycogenolysis and glycolysis, leading to muscle lactate production and accumulation, and subsequently, to increased blood concentrations. High elevations of blood lactate concentrations are accompanied by systemic acidosis [17], which is often seen as the likely triggering factor of accidents in SCT carriers [13]. The main reason for this is that acidosis decreases, by the Bohr effect, the affinity of hemoglobin (Hb) for oxygen, thus releasing it early in the microcirculation so that HbS polymerization, and consequently sickling, is favored [18].

The persistence of risk of VOC and complications several minutes after exercise [14]
lies in the combination of two particularities of the postexercise blood lactate kinetics. First,
lactate release by muscles continues for several minutes after exercise completion [19],
leading to a postexercise increase of blood lactate concentrations during this period [20].
Second, blood lactate concentrations remain elevated for 30-45 min after intense exercise,
disturbing the acid/base balance for a long period postexercise [20] that may potentially
favor the occurrence of VOC and accidents several minutes after intense exercise.

The lower index of oxygen supply to tissues and muscle oxidative potential (e.g., cytochrome c oxidase activity) [8,21] provide support for the hypothesis of a higher nonoxidative glycolytic energy supply, and consequently, higher blood lactate accumulation in response to maximal exercise in SCT [20], giving carriers a possibly augmented risk of exercise-related complications. However, our knowledge of lactate metabolism in the context of SCT is relatively sparse (restricted to blood data) and contradictory [20,22–29]. For instance, Freund et al. [20] found higher, Gozal et al. [22], Bilé et al. [24] and Sara et al. [25] found lower, and Marlin et al. [26,30] found similar blood lactate concentrations in SCT carriers compared to healthy controls in response to incremental exercises up to exhaustion. Bilé et al. [27] also found similar blood lactate concentrations in SCT carriers and control counterparts during and after repetition of 6-s maximal exercise bouts on a cycle ergometer. The conflicting results between these studies might be related to the low number of subjects studied (n ≤ 9) [20,22,24–27,30], differences in the types of exercise performed [27], different environments [23] and different physical ability between the studied populations [20]. Moreover, because of silent/subclinical repercussions of SCT [8,21,31], one cannot exclude that the same physical activity (which is kind of a training load) results in divergent physical ability in SCT carriers and healthy subjects. In that context, it may also be important to take into account the daily physical activity among the studied populations [21,31]. Complementary studies on lactate metabolism in exercising SCT carriers are thus warranted.

Thalassemia constitute another type of genetic mutation frequently observed in African origin populations. SCT is singularly associated with α-thalassemia (α-t). Subjects with the dual hemoglobinopathy (SCTα-t) often display lower HbS percentage and microcytosis [32,33]. In several respects, these particularities mitigate pathophysiology of sickle cell disease by favoring the flow of red blood cells through the capillaries, and by
dampening the risk of sickling [32,34]. From that point of view, α-thalassemia deserves to be considered.

The present study aimed to assess parameters of lactate metabolism in carriers of SCT in response to short, high-intensity exercise, and parameters of lactate time-course during the subsequent recovery. The studied parameters refer mainly (i) to lactate accumulation in different compartments (muscle and blood), (ii) to sarcolemmal lactate transport and its regulatory mechanisms, and (iii) to lactate removal ability.

## 2. Methods

### 2.1. Subjects

Thirty adult Cameroonian male SCT carriers (SCT, *n* = 15) and healthy subjects (CON, *n* = 15), with or without α-thalassemia, volunteered to participate in the study. They were assigned to one of the four groups: CON (*n* = 10), CONα-t (*n* = 5), SCT (*n* = 6) and SCTα-t (*n* = 9). Recruitment was conducted by posted notices and word of mouth in the students' community of the University of Yaoundé. Age, height and weight were 24 ± 2 years, 173 ± 5 cm, and 67 ± 5 kg (means ± standard deviation). The study was conducted at the General Hospital of Yaoundé in Cameroon. The study conformed to the guidelines set by the Declaration of Helsinki for human studies and was approved by the local ethics committee (no. 10-12-2005). Before giving their written informed consent, all subjects were fully informed of the objectives and possible risks and discomforts due to the experiments.

Volunteers who (a) presented a hemoglobinopathy other than SCT and α-thalassemia, (b) had suffered from a malaria episode within the previous 2 months, (c) were taking any medications, (d) were HIV carriers, (e) were taking part in another research program and/or (f) were smokers and/or regular alcohol drinkers, were not included in the study. At inclusion, blood samples were drawn from the antecubital vein of the nondominant arm at rest, and blood samples were then assayed for Hb and α-thalassemia.

### 2.2. Experimental Design

The protocol consisted of three visits (V1–V3) which took place a week apart.

#### 2.2.1. Inclusion (V1)

All prospective subjects underwent a thorough physical examination, anthropometric measurements and blood sampling. Blood samples were drawn from the antecubital vein of the nondominant arm at rest and assayed for Hb. Positive test results for SCT were determined by the presence of HbS at a level lower than 50% of total hemoglobin using HPLC. The presence of α-t was detected with a single-tube, multiplex-PCR assay, capable of detecting any combination of the six common single and double gene deletions in α-t. Only one form of α-t was found in the present study, the heterozygous form marked by the deletion of 3.7 kb of DNA containing one of the two linked α-globin genes (αα/-α [3,7]). Subjects also performed preliminary incremental and maximal exercise bouts to become familiar with the procedures.

#### 2.2.2. Incremental Exercise Test to Exhaustion (V2)

Subjects performed a graded exercise test using a leg-cycle ergometer (Kettler, Ense-Parsit, Germany). The exercise stopped at volitional exhaustion i.e., when the subjects were no longer able to sustain the work rate at the required pedaling frequency of 70 rpm. The exercise started at 70 W. After 3 min of exercise at this load, the work rate increased by 35 W every 3 min until volitional exhaustion. Heart rate (HR, beats·min⁻¹) was measured continuously using a chest belt (Polar Electro, Kempele, Finland). This exercise session was used for determination of maximal heart rate (HRmax, beats·min⁻¹) and the work rate associated with HRmax (Pmax, W and W·kg⁻¹).
### 2.2.3. Short High-Intensity Exercise Bout (V3)

For the short high-intensity exercise, subjects were requested to lie down on a bed in the dorsal decubitus position. Then, the right leg was prepared for muscle biopsy. After shaving, asepsis was obtained using alcohol and iodized derivatives, and a local anesthesia of cutaneous and subcutaneous tissues was made (2% lidocaine), without crossing the muscular aponeurosis. An incision not exceeding 8 mm broad was made (at a level corresponding to one-third of the distance from the upper margin of the patella to the anterior superior iliac spin) until the crossing of the epimysium. A temporary bandage protected the incision until subsequent (post exercise) muscle biopsy (vide infra). After 30 min of rest, a hyperemic cream (Dolpyc®, Pfizer, New York, NY, USA) was applied to the left earlobe for postexercise blood micropunctures. Then, the volunteers performed a 10-min warm-up at a heart rate of 130 beats·min⁻¹ (~50% of Pmax). After a 5-min rest, a blood micropuncture (20 µL) was collected from the right earlobe (pre-exercise value) and the hyperemic cream was removed from the left earlobe. Then, the subjects cycled for 2 min at 110% of Pmax. Immediately at exercise completion, the muscle biopsy was rapidly performed and immediately immersed in liquid nitrogen. The delay between exercise completion and freezing averaged 10 s. Hemostasis was then ensured by a 5-min compression, and the access closed by sterile strips. The biopsy was used for determination of (i) postexercise muscle metabolite concentration and (ii) muscle content of proteins of interest (vide infra). Blood micropunctures (20 µL) were also collected from the left earlobe at exercise completion, and thereafter at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 15, 20, 25, 30, 40, 50, 60, 70 and 80 min of passive recovery. Arterialized capillary blood sampled at the earlobe was diluted in a hemolyzing solution and stored at 4 °C until analysis. Blood samples were used to determine the time-course of lactate and glucose concentrations during recovery.

### 2.3. Blood Lactate and Glucose Concentrations and Their Time-Courses during Recovery

Lactate and glucose concentrations were determined enzymatically in whole blood using a YSI 2300 analyzer (YSI Inc., Yellow Springs, OH, USA).

Individual blood lactate recovery curves were fitted to the biexponential time function [35].

$$La(t) = [\text{lactate}]_b(0) + A_1(1 - e^{-\gamma_1 \cdot t}) + A_2(1 - e^{-\gamma_2 \cdot t}) \quad (1)$$

where [lactate]b(0) and La(t) (mmol·L⁻¹) are blood lactate concentrations at exercise completion and at a given time during recovery, respectively. Concentration parameters A₁ and A₂ (mmol·L⁻¹) are the amplitudes of the exponential functions. The velocity constants γ₁ and γ₂ (min⁻¹) represent the ability to exchange lactate between the previously active muscles and the blood and the overall ability to remove lactate, respectively [36]. The blood lactate recovery curves were fitted to Equation (1) by iterative nonlinear regression using KaleidaGraph 4.0 software (Synergy Software, Reading, PA, USA) to determine the values of [lactate]b(0), A₁, γ₁, A₂, and γ₂.

### 2.4. Muscle Analyses

Concerning the biochemical analyses, a first part of the postexercise muscle samples was freeze dried (Lyovac GT2, Leybol-Heraeus, Köln, Germany), dissected free from connective and fatty tissue and blood, and powdered in a chamber of controlled humidity (<40% relative humidity). For metabolites concentration determination, muscle powder was extracted with HClO₄ (650 mmol·L⁻¹), neutralized, and assayed enzymatically by fluorometric analysis. Metabolite concentrations are expressed in millimoles per kilogram tissue dry mass (mmol·kg⁻¹). For LDH isoforms determination, samples were placed into an ice-cold homogenization buffer (30 mg wet weight/mL) containing: 5 mM Hepes (pH 8.7), 1 mM EGTA, 1 mM dithiothreitol, 5 Mm MgCl₂, and 0.1% Triton. Samples were homogenized using a micro-glass hand homogenizer and were incubated for 60 min at 0 °C to ensure complete enzyme extraction. The LDH isoenzyme profile was determined using
agarose gel electrophoresis (Sigma LDH reagent kit, Sigma) at 200 V for 90 min. Isoenzyme bands were visualized and quantified using an image analysis system (Bio-Rad).

The second part of the biopsy was used for the quantification of selected proteins as previously described [37]. Approximately 30 mg of muscle were homogenized (Polytron 2100, Kinematica, Newark, NJ, USA) in a sucrose buffer (250 mM sucrose, 30 mM HEPES, 2 mM EGTA, 40 mM NaCl, 2 mM PMSF, pH 7.4) and centrifuged at 1000× g for 5 min. This procedure removed heavy material, including a fraction of the mitochondria. The supernatant was spun at 190,000× g for 90 min at 4 °C. The new supernatant (cytosolic fraction) was stored at −80 °C, while the new pellet (total muscle membrane fraction, including sarcolemmal and mitochondrial membrane fractions) was resuspended in Tris-SDS (10 mM Tris, 4% SDS, 1 mM EDTA, 2 mM PMSF, pH 7.4). Protein content was determined with a BSA standard (DC protein assay, Bio-Rad, Herlev, Denmark). Ten micrograms of protein from each sample were subjected to SDS-PAGE (excel 8–18% gradient gel; Amersham Biosciences, Uppsala, Sweden) and electroblotted to a Immobilon-P transfer membrane (Millipore, Copenhagen, Denmark). A Ponceau staining allowed us to check the homogeneity of load between wells. The membrane was then blocked with a buffer containing 1% BSA, 0.1% Tween 20, and 0.5% low fat milk and further incubated with the primary antibody diluted in the same blocking buffer. After treatment with the secondary antibody and repeated washing, the membrane was incubated with enhanced chemiluminescence reagent (Amersham Biosciences) and visualized on a hyper film (Amersham Biosciences). Quantification of the selected protein was performed by scanning the film and analyzing band densities with the SigmaGel software (SPSS, Chicago, IL, USA). The membrane-bound lactate/H⁺ cotransporter MCT1 and MCT4 (both 43 kDa) were measured on the muscle membrane fraction, whereas the CAII and CAIII (both 31 kDa) were measured on the cytosolic fraction. The antibodies for NHE1 (no. MAB3140), MCT1 (no. AB3540P), MCT4 (no. AB3316P), and CAII (no. AB1828) were purchased from Chemicon (Chandlers Ford, UK), from Spectral Diagnostics (Toronto, Canada) for CAIII (no. 4020), and from Santa Cruz Biotechnology INC (Dallas, TX, USA) for β2 AR (sc-569). Some membranes were reused after treatment with a stripping solution (Re-Blot Plus, Chemicon).

## 2.5. Statistical Analysis

Normality of distribution was tested by a Shapiro-Wilk test. Descriptive statistics are expressed as means (standard deviation) or as median (minimum-maximum). A two-way ANOVA was used to determine the effects of HbS, α-thalassemia and their interaction on the different measured parameters (StatView, SAS Institute, Cary, NC, USA). Excepted some hematological data, no effects of α-t and interactions SCT:α-t were observed on the variables of interest (Supplemental Tables S1–S3). Therefore, subjects with and without α-t were pooled in the SCT and CON groups. T-test and Mann-Whitney test were used to determine the effect of HbS on the different measured parameters (JASP 0.11.1, https://jasp-stats.org/, accessed on 30 October 2021). Differences between values were considered to be significant for $p \le 0.05$.

## 3. Results

The anthropometric, physiological and hematological characteristics of the subjects are reported in Table 1 [21]. The two groups of subjects were matched in terms of age, body mass, maximal heart rate, exercise capacity (assessed by $P_{max}$) and daily energy expenditure, suggesting that the groups were homogenous regarding physical characteristics and fitness. In addition, MCV and MCH were lower in SCT likely due to the higher proportion of α-t in this group. None of the subjects experienced adverse events during or after either the incremental or short supramaximal exercise bouts.
<table><caption>**Table 1.** Some anthropometric and physiological characteristics and hematological data of the subjects.</caption><thead><tr><th></th><th>CON<br>(n = 15)</th><th>SCT<br>(n = 15)</th><th>p Value</th></tr></thead><tbody><tr><td colspan="4">Anthropometric and physiological characteristics</td></tr><tr><td>Age (year)</td><td>24 (2)</td><td>23 (2)</td><td>0.052</td></tr><tr><td>Body mass (kg)</td><td>66 (5)</td><td>69 (6)</td><td>0.151</td></tr><tr><td>P<sub>max</sub> (W)</td><td>210 (170–241)</td><td>210 (140–245)</td><td>0.475</td></tr><tr><td>P<sub>max</sub> (W·kg<sup>-1</sup>)</td><td>3.02 (0.36)</td><td>3.01 (0.40)</td><td>0.920</td></tr><tr><td>DEE (kJ·day<sup>-1</sup>)</td><td>10,868 (1474)</td><td>11,664 (1321)</td><td>0.131</td></tr><tr><td colspan="4">Hemoglobin and hematological data</td></tr><tr><td>HbS (%)</td><td>not present</td><td>34.3 (3.6)</td><td>na</td></tr><tr><td>Hct (%)</td><td>43.0 (2.7)</td><td>43.2 (2.8)</td><td>0.826</td></tr><tr><td>MCV (fL)</td><td>84.71 (5.37)</td><td>80.00 (3.87)</td><td>0.010</td></tr><tr><td>MCH (pg)</td><td>27.29 (2.08)</td><td>25.93 (1.39)</td><td>0.044</td></tr><tr><td>MCHC (g·dL<sup>-1</sup>)</td><td>32.17 (0.67)</td><td>32.33 (0.56)</td><td>0.483</td></tr><tr><td>RBC (M·µL<sup>-1</sup>)</td><td>5.09 (0.42)</td><td>5.42 (0.45)</td><td>0.053</td></tr></tbody></table>

Values are mean (SD) or median (min-max). P<sub>max</sub>: maximal power; DEE: daily energy expenditure. Hb: hemoglobin; Hct: hematocrit; MCV: mean cell volume; MCH: mean cell hemoglobin; MCHC: mean cell hemoglobin concentration; RBC: red blood cell; WBC: white blood cell; Lymp: lymphocyte; na: not applicable.

### 3.1. Blood Lactate Response to Short Supramaximal Exercise

At rest, blood lactate concentrations were not different between groups (Table 2). In response to the short supramaximal exercise bout, blood lactate concentrations increased drastically, but to a lesser extent in SCT carriers (Table 2).

<table><caption>**Table 2.** Blood and muscle data.</caption><thead><tr><th></th><th>CON<br>(n = 15)</th><th>SCT<br>(n = 15)</th><th>p Value</th></tr></thead><tbody><tr><td colspan="4">Blood lactate concentrations</td></tr><tr><td>[lactate]<sub>b</sub>(r) (mmol·L<sup>-1</sup>)</td><td>1.356 (0.336)</td><td>1.301 (0.323)</td><td>0.648</td></tr><tr><td>[lactate]<sub>b</sub>(0) (mmol·L<sup>-1</sup>)</td><td>8.59 (1.40) [14]</td><td>7.08 (1.57)</td><td>0.011</td></tr><tr><td colspan="4">Bicarbonate-dependent muscle pH regulation mechanisms</td></tr><tr><td>CAII (a.u.)</td><td>1.28 (0.40) [13]</td><td>1.43 (0.36) [14]</td><td>0.317</td></tr><tr><td>CAIII (a.u.)</td><td>1.03 (0.34) [13]</td><td>1.05 (0.24) [13]</td><td>0.857</td></tr><tr><td>NBC (a.u.)</td><td>3.98 (0.67) [14]</td><td>3.95 (1.06) [13]</td><td>0.928</td></tr><tr><td colspan="4">Sarcolemmal H<sup>+</sup> transport</td></tr><tr><td>MCT1 (a.u.)</td><td>2.14 (0.53) [14]</td><td>2.33 (0.61) [13]</td><td>0.392</td></tr><tr><td>MCT4 (a.u.)</td><td>1.18 (1.75–4.81) [14]</td><td>2.70 (1.34–5.78) [14]</td><td>0.006</td></tr><tr><td colspan="4">Muscle metabolite concentrations</td></tr><tr><td>[lactate]<sub>m</sub>(0) (mmol·kg<sup>-1</sup> d.m.)</td><td>132 (95–201) [13]</td><td>113 (83–130)</td><td>0.022</td></tr><tr><td>[pyruvate]<sub>m</sub>(0) (mmol·kg<sup>-1</sup> d.m.)</td><td>1.85 (0.63–5.76) [13]</td><td>2.07 (1.13–3.59)</td><td>0.914</td></tr><tr><td>[lactate]<sub>m</sub>(0)/[pyruvate]<sub>m</sub> ratio</td><td>60.7 (26.3–225.5) [13]</td><td>55.2 (31.5–99.3)</td><td>0.440</td></tr><tr><td>[ATP]<sub>m</sub>(0) (mmol·kg<sup>-1</sup> d.m.)</td><td>14.4 (9.0–18.3) [13]</td><td>12.6 (9.6–21.9)</td><td>0.908</td></tr><tr><td>[ADP]<sub>m</sub>(0) (mmol·kg<sup>-1</sup> d.m.)</td><td>6.0 (2.60–9.10) [13]</td><td>6.70 (3.2–10.3)</td><td>0.903</td></tr><tr><td>[ATP]<sub>m</sub>/[ADP]<sub>m</sub>(0)</td><td>2.73 (1.22–4.38) [13]</td><td>1.96 (1.30–4.56)</td><td>0.339</td></tr></tbody></table>
<table><caption>**Table 2.** *Cont.*</caption><thead><tr><th></th><th>CON<br>(n = 15)</th><th>SCT<br>(n = 15)</th><th>p Value</th></tr></thead><tbody><tr><td colspan="4">LDH isoform proportions</td></tr><tr><td>M-LDH (%)</td><td>0.81 (0.71–0.84) [13]</td><td>0.81 (0.63–0.88)</td><td>0.610</td></tr><tr><td>H-LDH (%)</td><td>0.19 (0.16–0.29) [13]</td><td>0.19 (0.12–0.37)</td><td>0.610</td></tr><tr><td colspan="4">β<sub>2</sub>-adrenergic receptors</td></tr><tr><td>β<sub>2</sub>AR (a.u.)</td><td>0.87 (0.13–1.60) [14]</td><td>0.25 (0.08–1.53) [11]</td><td>0.021</td></tr></tbody></table>

Values are mean (SD) or median (min-max). b: blood, m: muscle; (r): rest; (0): exercise completion. CA: carbonic anhydrases; NBC: sodium bicarbonate cotransporter; MCT: monocarboxylate transporter (lactate/H⁺ symporter); a.u.: arbitrary units; ATP: adenosine triphosphate; ADP: adenosine diphosphate; d.m.: dry muscle, M-LDH and H-LDH: proportion of muscle and heart isoforms of lactate dehydrogenase; β₂AR: β₂-adrenergic receptor; [n]: number of subjects if different from total group.

## 3.2. Muscle pH Regulation, Lactate Transport, Metabolite Concentrations and Isoforms of Lactate Dehydrogenase

The muscle content of carbonic anhydrase (CA) II and III, sodium-bicarbonate cotransporter (NBC) and monocarboxylate (MCT) 1 was not different between groups. On the other hand, the muscle content of MCT4 was higher, and that of β₂-adrenergic receptor was lower in SCT compared to controls (Table 2). Furthermore, muscle lactate concentrations were significantly lower in carriers of SCT in response to the short supramaximal exercise (Table 2). Concentrations of other muscle metabolites did not diverge between groups (Table 2). Proportions of M and H forms of lactate dehydrogenase (M-LDH and H-LDH, respectively) were not different between groups (Table 2).

## 3.3. Blood Lactate and Glucose Kinetics during Recovery

Time courses of blood lactate concentrations during recovery displayed typical bi-exponential shapes (Figure 1) [38]. γ₁, which assesses the lactate exchange ability between the previously active muscles and the blood, was not different between groups. On the other hand, the lactate removal ability was significantly higher in the SCT carriers, as demonstrated by their higher γ₂ values compared to their control counterparts (Table 3).

<table><caption>**Table 3.** Blood lactate kinetics and glucose/lactate interaction parameters during recovery.</caption><thead><tr><th></th><th>CON<br>(n = 15)</th><th>SCT<br>(n = 15)</th><th>p Value</th></tr></thead><tbody><tr><td colspan="4">Blood lactate kinetics parameters</td></tr><tr><td>γ₁ (min<sup>-1</sup>)</td><td>0.207 (0.086) [14]</td><td>0.227 (0.104)</td><td>0.586</td></tr><tr><td>γ₂ (min<sup>-1</sup>)</td><td>0.045 (0.011) [14]</td><td>0.061 (0.022)</td><td>0.020</td></tr><tr><td>[lactate]<sub>b</sub>peak (mmol·L<sup>-1</sup>)</td><td>12.1 (1.7) [14]</td><td>10.4 (1.6)</td><td>0.009</td></tr><tr><td colspan="4">Cross-over point of blood glucose and lactate concentrations</td></tr><tr><td>Concentration (mmol·L<sup>-1</sup>)</td><td>5.21 (0.64) [14]</td><td>4.98 (0.34)</td><td>0.242</td></tr><tr><td>Time into recovery (min)</td><td>36.5 (26.3–66.9) [14]</td><td>30.8 (22.0–36.1)</td><td>0.012</td></tr></tbody></table>

Values are mean (SD) or median (min-max). A₁: amplitude of exponential term describing lactate appearance in the blood; γ: velocity constant denoting the lactate exchange ability between the previously active muscle and the blood; A₂: amplitude of exponential term describing lactate disappearance from the blood; γ: velocity constant denoting the lactate removal ability; peak: peak value observed during recovery; [n]: number of subjects if different from total group.
<figure><img src="image_4.png" /><figcaption>**Figure 1.** Typical recovery time-courses of blood lactate (black circles) and glucose (grey squares) concentrations obtained in control subjects (panels A–C) and SCT carriers (panels D–F).</figcaption></figure>

As recently depicted, a rebound of glycemia was observed after 20–50 min of recovery [38]. The cross-over point between the glycemia and blood lactate concentration curves took place at the same concentrations among groups but occurred earlier in the SCT groups compared to the control groups (Table 3).

**4. Discussion**

The aim of the present study was to improve our knowledge of lactate metabolism in response to high-intensity exercise in SCT carriers. The main findings were that, compared to control subjects, SCT carriers exhibited (i) lower muscle and blood lactate accumulations in response to short high-intensity exercise, (ii) a higher muscle content of MCT4 and (iii) a more rapid decrease of blood lactate levels during the subsequent recovery.

**4.1. *Metabolic Response to Short Supramaximal Exercise in SCT Carriers***

In the present study, we found lower blood lactate accumulation in response to short high-intensity exercise in SCT carriers. This observation, although surprising in the light of the literature suggesting a higher contribution of the nonoxidative glycolytic pathway in energy contribution [8,21], is actually reminiscent of previous studies [22–24]. Because capillary density, which determines lactate release from muscles [39], was lower in SCT carriers than in controls in the present study [21], we initially hypothesized (H1) that
the lower blood lactate concentrations in response to short high-intensity exercise might have been due to a slower lactate release from the active muscles. We also hypothesized (H2) that the resulting retention of lactate and $H^+$ in muscle may augment the acid/base balance disturbances and induce a long-term responsive upregulation of muscle buffering mechanisms in SCT carriers. Concerning H2, no divergences were noticed between groups concerning the muscle content of CAII, CAIII and NBC, suggesting the lack of particular adaptations in the bicarbonate-related mechanisms of muscle pH regulation with SCT. Along the same line, the muscle content of MCT1, which cotransport lactate and $H^+$ in a 1:1 ratio and thus may participate in the muscle pH regulation [40] was not different between groups. The lack of difference in MCT1 between groups is not so surprising inasmuch as MCT1 is mainly involved in lactate and $H^+$ uptake by myocytes [41]. On the other hand, interesting results were observed on the muscle content of MCT4 which was significantly higher with SCT in the present study. MCT4 is particularly involved in lactate and $H^+$ extrusion from the myocytes [42] and is therefore a strong contributor to pH regulation during high-intensity exercise [43].

By essence (lactate-$H^+$ coupled-transport), MCT4 is also the main pathway by which lactate is extruded from the active muscles [42]. From that point of view, the higher muscle MCT4 content may counterbalance the lower density of the muscle capillary network [21] to maintain an adequate lactate release from the muscles. In accordance with this line of reasoning, but contrary to our initial hypothesis (H1), the lactate exchange ability between muscle and blood (assessed by $\gamma_1$) was not different among groups and therefore cannot explain the lower blood lactate accumulation. Other mechanisms should be involved. A previous study reported that MCT4, was upregulated by hypoxia [44]. Whether the higher muscle MCT4 content we observed in the present study in SCT carriers is related to (i) hypoxic episodes, (ii) an adaptive response to regular muscular acid/base balance disturbances, (iii) a compensatory mechanism of lower capillary density, or (iv) a combination of the previous possibilities, remains to be determined.

Because the lactate exchange ability cannot be incriminated to explain the lower postexercise blood lactate concentrations, then lower muscle lactate accumulation must be considered. This idea may appear surprising given the lower index of oxygen supply to tissues and the depressed muscle oxidative potential reported in SCT carriers [8,21]. However, significantly lower muscle lactate concentrations were measured in the SCT carriers than in the control subjects. The lower muscle lactate accumulation in SCT carriers cannot be attributed to a default in muscle glycolytic potential since the key enzymes of glycolysis [31] and the M-LDH proportion (Table 2), which all drive lactate production, were similar among groups. Consequently, a lower activation of glycogenolysis and/or glycolysis should be considered. If a lower activation occurred, it could not be mediated by changes in the ATP/ADP ratio since this ratio was not different among groups (Table 2). On the other hand, lactate production is known to be intimately related to muscle glycolytic pathway activation by catecholamines [45]. Interestingly, the sarcolemmal content of $\beta_2$-adrenergic receptors was depressed in the SCT groups, that might to some extent support the idea of lower activation of glycogenolysis and glycolysis in the carriers and their lower muscle lactate accumulation. Other possibilities may exist. For example, a higher lactate removal ability during exercise could be evoked and in view of the results obtained during recovery (vide infra), one cannot totally exclude this possibility. As a whole, further studies are necessary to understand the intriguing lactate metabolism depicted in SCT carriers.

## 4.2. Postexercise Blood Lactate Kinetics and Its Relation with Glycemia

During recovery, blood lactate concentrations remained elevated (>5 mmol·L⁻¹) for 20–50 min (Figure 1) [38]. Interestingly, blood lactate levels during this period were lower and decreased more rapidly in the SCT carriers than in their control counterparts (Table 3). This can be attributed to the higher lactate removal ability during recovery (assessed by $\gamma_2$) observed in SCT carriers (Table 3). This latter result reinforces the possibility of a higher lactate removal during exercise (vide supra) in SCT carriers.
Correlated with the muscle oxidative capacity (citrate synthase activity and mitochondrial respiration) and content of MCT1 (involved in lactate uptake by the muscle) [46,47], γ₂ is believed to be mainly attributed to oxidation of lactate during recovery. From that point of view, the higher γ₂ values of SCT carriers suggest a higher lactate oxidation during recovery in these subjects. The second main fate of lactate during recovery is hepatic gluconeogenesis [48]. The quicker lactate disappearance rate constant in SCT carriers may also indicate an earlier lactate uptake by the liver [48]. This hypothesis is supported by the fact that the delayed postexercise rebound of glycemia attributed to glucose and lactate interactions (via gluconeogenesis) [38] was observed earlier postexercise in SCT carriers (Table 3). Lactate uptake by the liver is intimately related to lactate delivery, and thus to local blood flow. Interestingly, local blood flow is driven by the sympathetic nervous system activation and especially its hormones: the catecholamines. If, as already suspected during exercise (*vide supra*), catecholamines action is mitigated, this would limit vasoconstriction at the splanchnic level, maintain hepatic local blood flow, preserve lactate delivery to the liver, and ultimately favor lactate uptake.

### 4.3. Effects of α-Thalassemia

In the present study, α-thalassemia did not induce any specific muscle metabolic responses/adaptations to exercise. This is reminiscent with the lack of effects of α-thalassemia on muscle structural and energetic characteristics previously reported in SCT and CON [31]. At the vascular level, α-thalassemia seems (i) to improve RBC deformability and blood apparent viscosity, (ii) to blunt inflammation and adhesion and (iii) to dampen microvascular remodeling [9,10,21]. Taken together, the present results and the literature seem to indicate that skeletal muscle (at least its structural and energetic characteristics as well as its metabolic responses to exercise) does not seem to take advantage of α-thalassemia whom effects at the vascular level seem to be tangible [9,10,21].

### 4.4. Clinical Relevance and Consequences on High-Intensity Exercise Performance

The lower index of oxygen supply to tissues and the depressed muscle oxidative potential [8,21] were evidence of a higher nonoxidative glycolytic energy supply, and consequently, of higher blood lactate accumulation in response to short high-intensity exercise in SCT [20]. However, contrary to this idea, we clearly demonstrated lower muscle and blood lactate accumulations delineating kind of a paradox in exercising SCT carriers.

The lower blood lactate accumulation may constitute a protective mechanism to limit blood acidification during and after exercise that may also contribute to restrict the risk of sickling and complications in SCT carriers. This protective mechanism may at least partly explain, despite substantial literature reporting sudden deaths in carriers of SCT, why these fatal episodes remain rare in respect to the prevalence of SCT in the considered populations [14]. Our results may also enlighten why severe complications have been observed almost exclusively after extreme exertional exercise which (i) may overwhelm this protective mechanism, and (ii) are often associated with dehydration and hypoxia that also worsen the risk of sickling and thus of VOC. Our results may also support the results of Nelson et al., who found no significant difference in the risk of death among soldiers with and without the sickle cell trait, although the authors noted a higher risk of exertional rhabdomyolysis in SCT carriers [49].

Moreover, the lower muscle lactate accumulation in response to high-intensity exercise may also partly explain why the prevalence of the trait is higher in the best athletes involved in short high-intensity exercise, e.g., short sprints [50,51]. Indeed, if during moderate-intensity exercise lactate can be used as an important energy substrate for muscle contraction [45], significant lactate accumulation and the accompanying acidosis may, on the contrary, lead to alterations of muscle function [52–59], although this view has been challenged [60,61]. Nevertheless, following this line of reasoning, the lower lactate accumulation in SCT carriers might account for better maintenance of muscle function
during exercise and thus explain the better performance during high-intensity exercise in
SCT carriers [50,51].

4.5. *Nutritional and Metabolic Flexibility Perspectives/Hypotheses*

During exercise, the use of a lactate clamp has been shown to increase lactate dis-
posal [45] and reduce glucose utilization [62]. Furthermore, lactate-supplemented sport
drinks have been shown to increase lactate disposal and to improve performance [63]. If
the higher lactate removal ability is confirmed in SCT, these previous studies suggest that
carriers may take more advantage than controls from lactate clamp or supplementation for
lactate utilization and physical performance. Besides, because blood lactate accumulation
limits lipolysis and free fatty acids oxidation [64], the greater lactate removal ability of
SCT carriers may, by lowering blood lactate levels, provide them a different substrate
partitioning and/or metabolic flexibility. Further studies are necessary to confirm these
possibilities/hypotheses.

4.6. *Limitations and Perspectives*

The main limitation of the present study is the low number of subjects in each group. This limitation may account for the lack of effects of α-thalassemia found at the muscular level [31]. Further studies involving a higher number of subjects are thus necessary to confirm or refute the lack of role of α-thalassemia at the muscular level. The present results should also be complemented with tracer studies. Such studies would make it possible to determine the effects of SCT on important parameters of lactate kinetics (e.g., lactate rates of appearance, disappearance and oxidation, as well as the metabolic clearance rate of lactate).

**5. Conclusions**

The main findings of the present study are that carriers of sickle cell trait displayed
(i) lower muscle and blood lactate accumulations in response to a short high-intensity
exercise bout, (ii) higher muscle MCT4 content and (iii) more rapid decrease of blood lactate
concentrations during recovery, than control counterparts. As a whole, the lower blood and
muscle lactate accumulations may, to some extent, act as protective mechanisms: (i) against
sickling and thus VOC, that may explain the relatively rare complications and sudden
death observed in SCT carriers, and (ii) against the deleterious intracellular effects of lactate
and associated acidosis on muscle function, that may explain the elevated presence of SCT
carriers among the best short-distance sprinters.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu14030501/s1, Table S1: Some anthropometric and physiological characteristics and hematological data of the subjects, Table S2: Blood and muscle data, Table S3: Blood lactate kinetics and glucose/lactate interaction parameters during recovery.

**Author Contributions:** Conception or design of the work: L.A.M., S.O.-E., L.F. Data acquisition, or analysis, or interpretation: L.A.M., S.O.-E., L.V., H.D., B.C., H.S., A.M., C.M., P.T., L.F. Drafting the work or revising it critically: L.A.M., S.O.-E., L.V., H.D., B.C., H.S., A.M., C.M., F.G., P.B., P.T., L.F. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by grants from the French Embassy in Cameroon and the Ministry of Higher Education of Cameroon.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Local Ethics Committee (no. 10-12-2005).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** Study protocol and data will be available 5 years following article publication to researchers who provide a methodologically sound proposal. Proposals should be directed to laurent.messonnier@univ-smb.fr. To gain access, data requestors will need to sign a data access agreement.
**Acknowledgments:** The logistic support offered by the Ministry of Public Health (Cameroon) is recognized. The authors thank all the subjects for their participation as well as J Castells, G Monchanin, P Berthon, G Lepape, D Gouttefangeas, M-P Blanc, C Nouedoui, and P Stoft for their helpful technical assistance.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Binder, A.R.; Jones, S.R. Prevalence and awareness of sickle cell hemoglobin in a military population. Determination by a rapid screening method. *JAMA* **1970**, *214*, 909–911. [CrossRef] [PubMed]

2. Binder, R.A.; Jones, S.R. Sickle-cell trait. *N. Engl. J. Med.* **1970**, *282*, 1158. [PubMed]

3. Jones, S.R.; Binder, R.A.; Donowho, E.M.J. Sudden death in sickle-cell trait. *N. Engl. J. Med.* **1970**, *282*, 323–325. [CrossRef] [PubMed]

4. Hoiberg, A.; Ernst, J.E.; Uddin, D. Sickle cell trait and glucose-6-phosphate dehydrogenase deficiency. Effects on health and military performance in black Navy enlistees. *Arch. Intern. Med.* **1981**, *141*, 1485–1488. [CrossRef] [PubMed]

5. Kark, J.A.; Posey, D.M.; Schumacher, H.R.; Ruehle, C.J. Sickle-Cell Trait as a Risk Factor for Sudden Death in Physical Training. *N. Engl. J. Med.* **1987**, *317*, 781–787. [CrossRef] [PubMed]

6. Murphy, J.R. Sickle cell hemoglobin (Hb AS) in black football players. *JAMA* **1973**, *225*, 981–982. [CrossRef]

7. Bergeron, M.F.; Cannon, J.G.; Hall, E.L.; Kutlar, A. Erythrocyte Sickling During Exercise and Thermal Stress. *Clin. J. Sport Med.* **2004**, *14*, 354–356. [CrossRef]

8. Connes, P.; Sara, F.; Hardy-Dessources, M.-D.; Marlin, L.; Etienne, F.; Larifla, L.; Saint-Martin, C.; Hue, O. Effects of short supramaximal exercise on hemorheology in sickle cell trait carriers. *Arbeitsphysiologie* **2006**, *97*, 143–150. [CrossRef]

9. Monchanin, G.; Connes, P.; Wouassi, D.; Francina, A.; Djoda, B.; Banga, P.E.; Owona, F.X.; Thiriet, P.; Massarelli, R.; Martin, C. Hemorheology, Sickle Cell Trait, and α-Thalassemia in Athletes: Effects of Exercise. *Med. Sci. Sports Exerc.* **2005**, *37*, 1086–1092. [CrossRef]

10. Monchanin, G.; Serpero, L.D.; Connes, P.; Tripette, J.; Wouassi, D.; Bezin, L.; Francina, A.; Ngongang, J.; De La Peña, M.; Massarelli, R.; et al. Effects of progressive and maximal exercise on plasma levels of adhesion molecules in athletes with sickle cell trait with or without α-thalassemia. *J. Appl. Physiol.* **2007**, *102*, 169–173. [CrossRef]

11. Martin, T.W.; Weisman, I.M.; Zeballos, R.J.; Stephenson, S.R. Exercise and hypoxia increase sickling in venous blood from an exercising limb in individuals with sickle cell trait. *Am. J. Med.* **1989**, *87*, 48–56. [CrossRef]

12. Bennett, M.A.; Heslop, R.W.; Meynell, M.J. Massive haematuria associated with sickle-cell trait. *BMJ* **1967**, *1*, 677–679. [CrossRef]

13. Anzalone, M.L.; Green, V.S.; Buja, M.; Sanchez, L.A.; Harrykissoon, R.I.; Eichner, E.R. Sickle cell trait and fatal rhabdomyolysis in football training: A case study. *Med. Sci. Sports Exerc.* **2010**, *42*, 3–7. [CrossRef] [PubMed]

14. Koppes, G.; Daly, J.; Coltman, C.; Butkus, D. Exertion-Induced rhabdomyolysis with acute renal failure and disseminated intravascular coagulation in sickle cell trait. *Am. J. Med.* **1977**, *63*, 313–317. [CrossRef]

15. Le Gallais, D.; Bile, A.; Mercier, J.; Paschel, M.A.; Tonellot, J.L.; Dauverchain, J.E. Exercise-induced death in sickle cell trait: Role of aging, training, and deconditioning. *Med. Sci. Sports Exerc.* **1996**, *28*, 541–544.

16. Rosenthal, A.M.; Parker, D.J. Collapse of a young athlete. *Ann. Emerg. Med.* **1992**, *21*, 1493–1498. [CrossRef]

17. Freund, H.; Lonsdorfer, J.; Oyono-Enguellé, S.; Lonsdorfer, A.; Bogui, P. Lactate exchange and removal abilities in sickle cell patients and in untrained and trained healthy humans. *J. Appl. Physiol.* **1992**, *73*, 2580–2587. [CrossRef]

18. Ueda, Y.; Nagel, R.L.; Bookchin, R.M. An increased Bohr effect in sickle cell anemia. *Blood* **1979**, *53*, 472–480. [CrossRef]

19. Juel, C.; Bangsbo, J.; Graham, T.; Saltin, B. Lactate and potassium fluxes from human skeletal muscle during and after intense, dynamic, knee extensor exercise. *Acta Physiol. Scand.* **1990**, *140*, 147–159. [CrossRef]

20. Freund, H.; Lonsdorfer, J.; Oyono-Enguellé, S.; Lonsdorfer, A.; Dah, C.; Bogui, P. Lactate Exchange and Removal Abilities in Sickle Cell Trait Carriers During and After Incremental Exercise. *Int. J. Sports Med.* **1995**, *16*, 428–434. [CrossRef]

21. Vincent, L.; Féasson, L.; Oyono-Enguellé, S.; Banimbek, V.; Denis, C.; Guarneri, C.; Aufradet, E.; Monchanin, G.; Martin, C.; Gozal, D.; et al. Remodeling of skeletal muscle microvasculature in sickle cell trait and α-thalassemia. *Am. J. Physiol. Circ. Physiol.* **2010**, *298*, H375–H384. [CrossRef] [PubMed]

22. Gozal, D.; Thiriet, P.; Mbala, E.; Wouassi, D.; Gelas, H.; Geyssant, A.; Lacour, J.R. Effect of different modalities of exercise and recovery on exercise performance in subjects with sickle cell trait. *Med. Sci. Sports Exerc.* **1992**, *24*, 1325–1331. [CrossRef] [PubMed]

23. Thiriet, P.; Wouassi, D.; Bitanga, E.; Lacour, J.R.; Gozal, D. Hyperoxia during recovery from consecutive anaerobic exercises in the sickle cell trait. *Eur. J. Appl. Physiol. Occup. Physiol.* **1995**, *71*, 253–258. [CrossRef] [PubMed]

24. Bile, A.; Le Gallais, D.; Mercier, B.; Martinez, P.; Ahmaidi, S.; Prefaut, C.; Mercier, J. Blood lactate concentrations during incremental exercise in subjects with sickle cell trait. *Med. Sci. Sports Exerc.* **1998**, *30*, 649–654. [CrossRef]

25. Sara, F.; Hardy-Dessources, M.-D.; Voltaire, B.; Etienne-Julan, M.; Hue, O. Lactic Response in Sickle Cell Trait Carriers in Comparison With Subjects With Normal Hemoglobin. *Clin. J. Sport Med.* **2003**, *13*, 96–101. [CrossRef]

26. Marlin, L.; Sara, F.; Antoine-Jonville, S.; Connes, P.; Etienne-Julan, M.; Hue, O. Ventilatory and Lactic Thresholds in Subjects with Sickle Cell Trait. *Int. J. Sports Med.* **2007**, *28*, 916–920. [CrossRef]
27. Bilé, A.; Le Gallais, D.; Mercier, B.; Martinez, P.; Ahmaidi, S.; Préfaut, C. Anaerobic Exercise Components During the Force-Velocity Test in Sickle Cell Trait. *Int. J. Sports Med.* **1996**, *17*, 254–258. [CrossRef]

28. Connes, P.; Hardy-Dessources, M.-D.; Hue, O. Counterpoint: Sickle cell trait should not be considered asymptomatic and as a benign condition during physical activity. *J. Appl. Physiol.* **2007**, *103*, 2138–2140. [CrossRef]

29. Le Gallais, D.; Lonsdorfer, J.; Bogui, P.; Fattoum, S. Point: Sickle cell trait should be considered asymptomatic and as a benign condition during physical activity. *J. Appl. Physiol.* **2007**, *103*, 2137–2138. [CrossRef]

30. Marlin, L.; Connes, P.; Antoine-Jonville, S.; Tripette, J.; Montout-Hedreville, M.; Sanouiller, A.; Etienne-Julan, M.; Hue, O. Cardiorespiratory responses during three repeated incremental exercise tests in sickle cell trait carriers. *Graefe's Arch. Clin. Exp. Ophthalmol.* **2007**, *102*, 181–187. [CrossRef]

31. Vincent, L.; Féasson, L.; Oyono-Enguéllé, S.; Banimbek, V.; Monchanin, G.; Dohbobga, M.; Wouassi, D.; Martin, C.; Gozal, D.; Geyssant, A.; et al. Skeletal muscle structural and energetic characteristics in subjects with sickle cell trait, α-thalassemia, or dual hemoglobinopathy. *J. Appl. Physiol.* **2010**, *109*, 728–734. [CrossRef] [PubMed]

32. Steinberg, M.; Embury, S.H. Alpha-thalassemia in blacks: Genetic and clinical aspects and interactions with the sickle hemoglobin gene. *Blood* **1986**, *68*, 985–990. [CrossRef] [PubMed]

33. Steinberg, M.H. Haemoglobin C/α Thalassaemia: Haematological and Biosynthetic Studies. *Br. J. Haematol.* **1975**, *30*, 337–342. [CrossRef] [PubMed]

34. Embury, S.H. Alpha thalassemia. A modifier of sickle cell disease. *Ann. N. Y. Acad. Sci.* **1989**, *565*, 213–221. [CrossRef] [PubMed]

35. Freund, H.; Oyono-Enguéllé, S.; Heitz, A.; Marbach, J.; Ott, C.; Zouloumian, P.; Lampert, E. Work rate-dependent lactate kinetics after exercise in humans. *J. Appl. Physiol.* **1986**, *61*, 932–939. [CrossRef] [PubMed]

36. Chatel, B.; Bret, C.; Edouard, P.; Oullion, R.; Freund, H.; Messonnier, L.A. Lactate recovery kinetics in response to high-intensity exercises. *Graefe's Arch. Clin. Exp. Ophthalmol.* **2016**, *116*, 1455–1465. [CrossRef]

37. Messonnier, L.; Kristensen, M.; Juel, C.; Denis, C. Importance of pH regulation and lactate/H+transport capacity for work production during supramaximal exercise in humans. *J. Appl. Physiol.* **2007**, *102*, 1936–1944. [CrossRef]

38. Messonnier, L.A.; Chatel, B.; Emhoff, C.-A.W.; Blervaque, L.; Oyono-Enguéllé, S. Delayed Rebound of Glycemia During Recovery Following Short-Duration High-Intensity Exercise: Are There Lactate and Glucose Metabolism Interactions? *Front. Nutr.* **2021**, *8*, 734152. [CrossRef]

39. Tesch, P.A.; Wright, J.E. Recovery from short term intense exercise: Its relation to capillary supply and blood lactate concentration. *Graefe's Arch. Clin. Exp. Ophthalmol.* **1983**, *52*, 98–103. [CrossRef]

40. Juel, C. Lactate-proton cotransport in skeletal muscle. *Physiol. Rev.* **1997**, *77*, 321–358. [CrossRef]

41. Chatel, B.; Bendahan, D.; Hourdé, C.; Pellerin, L.; Lengacher, S.; Magistretti, P.; Le Fur, Y.; Vilmen, C.; Bernard, M.; Messonnier, L.A. Role of MCT1 and CAII in skeletal muscle pH homeostasis, energetics, and function: In vivo insights from MCT1 haploinsufficient mice. *FASEB J.* **2017**, *31*, 2562–2575. [CrossRef] [PubMed]

42. Manning Fox, J.E.; Meredith, D.; Halestrap, A.P. Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. *J. Physiol.* **2000**, *529*, 285–293. [PubMed]

43. Juel, C. Regulation of pH in human skeletal muscle: Adaptations to physical activity. *Acta Physiol.* **2008**, *193*, 17–24. [CrossRef] [PubMed]

44. Ullah, M.S.; Davies, A.J.; Halestrap, A.P. The Plasma Membrane Lactate Transporter MCT4, but Not MCT1, Is Up-regulated by Hypoxia through a HIF-1α-dependent Mechanism. *J. Biol. Chem.* **2006**, *281*, 9030–9037. [CrossRef]

45. Messonnier, L.A.; Emhoff, C.-A.W.; Fattor, J.A.; Horning, M.A.; Carlson, T.J.; Brooks, G.A. Lactate kinetics at the lactate threshold in trained and untrained men. *J. Appl. Physiol.* **2013**, *114*, 1593–1602. [CrossRef]

46. Thomas, C.; Perrey, S.; Lambert, K.; Hugon, G.; Mornet, D.; Mercier, J. Monocarboxylate transporters, blood lactate removal after supramaximal exercise, and fatigue indexes in humans. *J. Appl. Physiol.* **2005**, *98*, 804–809. [CrossRef]

47. Thomas, C.; Sirvent, P.; Perrey, S.; Raynaud, E.; Mercier, J. Relationships between maximal muscle oxidative capacity and blood lactate removal after supramaximal exercise and fatigue indexes in humans. *J. Appl. Physiol.* **2004**, *97*, 2132–2138. [CrossRef]

48. Chioléro, R.; Tappy, L.; Gillet, M.; Revelly, J.-P.; Roth, H.; Cayeux, C.; Schneiter, P.; Leverve, X. Effect of Major Hepatectomy on Glucose and Lactate Metabolism. *Ann. Surg.* **1999**, *229*, 505–513. [CrossRef]

49. Nelson, D.A.; Deuster, P.A.; Carter, R., III; Hill, O.T.; Wolcott, V.L.; Kurina, L.M. Sickle Cell Trait, Rhabdomyolysis, and Mortality among U.S. Army Soldiers. *N. Engl. J. Med.* **2016**, *375*, 435–442. [CrossRef]

50. Bilé, A.; Le Gallais, D.; Mercier, J.; Bogui, P.; Préfaut, C. Sickle Cell Trait in Ivory Coast Athletic Throw and Jump Champions, 1956–1995. *Int. J. Sports Med.* **1998**, *19*, 215–219. [CrossRef] [PubMed]

51. Marlin, L.; Etienne-Julan, M.; Le Gallais, D.; Hue, O. Sickle Cell Trait in French West Indian Elite Sprint Athletes. *Int. J. Sports Med.* **2005**, *26*, 622–625. [CrossRef] [PubMed]

52. Favero, T.G.; Zable, A.C.; Colter, D.; Abramson, J.J. Lactate inhibits Ca2+-activated Ca2+-channel activity from skeletal muscle sarcoplasmic reticulum. *J. Appl. Physiol.* **1997**, *82*, 447–452. [CrossRef] [PubMed]

53. Hogan, M.C.; Gladden, L.B.; Kurdak, S.S.; Poole, D.C. Increased [lactate] in working dog muscle reduces tension development independent of pH. *Med. Sci. Sports Exerc.* **1995**, *27*, 371–377. [CrossRef] [PubMed]

54. Kristensen, M.; Albertsen, J.; Rentsch, M.; Juel, C. Lactate and force production in skeletal muscle. *J. Physiol.* **2005**, *562*, 521–526. [CrossRef]

55. Fitts, R. Cellular mechanisms of muscle fatigue. *Physiol. Rev.* **1994**, *74*, 49–94. [CrossRef]
56. Fitts, R.H. The Role of Acidosis in Fatigue: Pro Perspective. *Med. Sci. Sports Exerc.* **2016**, *48*, 2335–2338. [CrossRef]

57. Metzger, J.M.; Fitts, R.H. Role of intracellular pH in muscle fatigue. *J. Appl. Physiol.* **1987**, *62*, 1392–1397. [CrossRef]

58. Nelson, C.R.; DeBold, E.P.; Fitts, R.H. Phosphate and acidosis act synergistically to depress peak power in rat muscle fibers. *Am. J. Physiol. Physiol.* **2014**, *307*, C939–C950. [CrossRef]

59. Sundberg, C.W.; Hunter, S.K.; Trappe, S.W.; Smith, C.S.; Fitts, R.H. Effects of elevated H+ and Pi on the contractile mechanics of skeletal muscle fibres from young and old men: Implications for muscle fatigue in humans. *J. Physiol.* **2018**, *596*, 3993–4015. [CrossRef]

60. Westerblad, H. Acidosis Is Not a Significant Cause of Skeletal Muscle Fatigue. *Med. Sci. Sports Exerc.* **2016**, *48*, 2339–2342. [CrossRef] [PubMed]

61. Nielsen, O.B.; de Paoli, F.V.; Overgaard, K. Protective effects of lactic acid on force production in rat skeletal muscle. *J. Physiol.* **2001**, *536*, 161–166. [CrossRef] [PubMed]

62. Emhoff, C.-A.W.; Messonnier, L.A.; Horning, M.A.; Fattor, J.A.; Carlson, T.J.; Brooks, G.A. Direct and indirect lactate oxidation in trained and untrained men. *J. Appl. Physiol.* **2013**, *115*, 829–838. [CrossRef]

63. Azevedo, J.L., Jr.; Tietz, E.; Two-Feathers, T.; Paull, J.; Chapman, K. Lactate, Fructose and Glucose Oxidation Profiles in Sports Drinks and the Effect on Exercise Performance. *PLoS ONE* **2007**, *2*, e927. [CrossRef] [PubMed]

64. Brooks, G.A.; Arevalo, J.A.; Osmond, A.D.; Leija, R.G.; Curl, C.C.; Tovar, A.P. Lactate in contemporary biology: A phoenix risen. *J. Physiol.* **2021**. [CrossRef] [PubMed]